Literature DB >> 7604360

An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group.

A C Bird, N M Bressler, S B Bressler, I H Chisholm, G Coscas, M D Davis, P T de Jong, C C Klaver, B E Klein, R Klein.   

Abstract

A common detection and classification system is needed for epidemiologic studies of age-related maculopathy (ARM). Such a grading scheme for ARM is described in this paper. ARM is defined as a degenerative disorder in persons > or = 50 years of age characterized on grading of color fundus transparencies by the presence of the following abnormalities in the macular area: soft drusen > or = 63 microns, hyperpigmentation and/or hypopigmentation of the retinal pigment epithelium (RPE), RPE and associated neurosensory detachment, (peri)retinal hemorrhages, geographic atrophy of the RPE, or (peri)retinal fibrous scarring in the absence of other retinal (vascular) disorders. Visual acuity is not used to define the presence of ARM. Early ARM is defined as the presence of drusen and RPE pigmentary abnormalities described above; late ARM is similar to age-related macular degeneration (AMD) and includes dry AMD (geographic atrophy of the RPE in the absence of neovascular AMD) or neovascular AMD (RPE detachment, hemorrhages, and/or scars as described above). Methods to take and grade fundus transparencies are described.

Entities:  

Mesh:

Year:  1995        PMID: 7604360     DOI: 10.1016/s0039-6257(05)80092-x

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  514 in total

Review 1.  Treatment of subfoveal choroidal neovascularisation in age related macular degeneration: focus on clinical application of verteporfin photodynamic therapy.

Authors:  G Soubrane; N M Bressler
Journal:  Br J Ophthalmol       Date:  2001-04       Impact factor: 4.638

2.  Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium.

Authors:  A D Marmorstein; L Y Marmorstein; M Rayborn; X Wang; J G Hollyfield; K Petrukhin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

3.  Risk of macular degeneration with statin use should be interpreted with caution.

Authors:  R van Leeuwen; J R Vingerling; P T de Jong
Journal:  BMJ       Date:  2001-12-01

4.  Extracts from "clinical evidence": age related macular degeneration.

Authors:  J J Arnold; S H Sarks
Journal:  BMJ       Date:  2000-09-23

Review 5.  Why study rod cell death in retinal degenerations and how?

Authors:  C E Remé; C Grimm; F Hafezi; H P Iseli; A Wenzel
Journal:  Doc Ophthalmol       Date:  2003-01       Impact factor: 2.379

6.  A whole-genome screen of a quantitative trait of age-related maculopathy in sibships from the Beaver Dam Eye Study.

Authors:  James H Schick; Sudha K Iyengar; Barbara E Klein; Ronald Klein; Karlie Reading; Rachel Liptak; Christopher Millard; Kristine E Lee; Sandra C Tomany; Emily L Moore; Bonnie A Fijal; Robert C Elston
Journal:  Am J Hum Genet       Date:  2003-04-24       Impact factor: 11.025

7.  CNV subtype in first eyes predicts severity of ARM in fellow eyes.

Authors:  S Abugreen; K A Muldrew; M R Stevenson; R VanLeeuwen; P T V M DeJong; U Chakravarthy
Journal:  Br J Ophthalmol       Date:  2003-03       Impact factor: 4.638

8.  Dynamic soft drusen remodelling in age-related macular degeneration.

Authors:  R Theodore Smith; Mahsa A Sohrab; Nicole Pumariega; Yue Chen; Jian Chen; Noah Lee; Andrew Laine
Journal:  Br J Ophthalmol       Date:  2010-06-07       Impact factor: 4.638

Review 9.  Aflibercept for intravitreal injection: in neovascular age-related macular degeneration.

Authors:  James E Frampton
Journal:  Drugs Aging       Date:  2012-10       Impact factor: 3.923

10.  Risk factors for age related maculopathy in a Japanese population: the Hisayama study.

Authors:  M Miyazaki; H Nakamura; M Kubo; Y Kiyohara; Y Oshima; T Ishibashi; Y Nose
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.